Cargando…

Application of VIP Care in Patients with Advanced Tumors in the Western Region of China

OBJECTIVE: The objective of this study is to explore the application of a very important person (VIP) intervention mode in patients with advanced tumors in the western region of China. METHODS: One hundred and sixty-three patients were randomly divided into a control and experimental groups. The con...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Xiaoqin, Peng, Yanqiong, Liu, Chonghua, Li, Fei, Zhang, Haiying, Liao, Jia, Wu, Guirong, Zeng, Xiaomei, Xie, Nan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9453040/
https://www.ncbi.nlm.nih.gov/pubmed/36093398
http://dx.doi.org/10.1155/2022/7834620
_version_ 1784785055137136640
author Zheng, Xiaoqin
Peng, Yanqiong
Liu, Chonghua
Li, Fei
Zhang, Haiying
Liao, Jia
Wu, Guirong
Zeng, Xiaomei
Xie, Nan
author_facet Zheng, Xiaoqin
Peng, Yanqiong
Liu, Chonghua
Li, Fei
Zhang, Haiying
Liao, Jia
Wu, Guirong
Zeng, Xiaomei
Xie, Nan
author_sort Zheng, Xiaoqin
collection PubMed
description OBJECTIVE: The objective of this study is to explore the application of a very important person (VIP) intervention mode in patients with advanced tumors in the western region of China. METHODS: One hundred and sixty-three patients were randomly divided into a control and experimental groups. The control group received routine care, and the experimental group received VIP future care. The willingness to end-of-life treatment, decision-making certainty, and quality of life were compared between the two groups before intervention (T0), after intervention (T1), and 1 month after intervention (T2). RESULTS: There were no significant differences in the basic data of the two groups. Unlike the control group, the experimental group preferred palliative care at the end of T1 (P < 0.05), and the acceptance rate of cardiopulmonary resuscitation and mechanical treatment decreased significantly. After the VIP intervention, the patient was transferred to the intensive care unit (ICU) (P < 0.05). After 1 month of intervention (T2), the results showed that the overall quality of life, physical discomfort, negative emotions, care and support, survival predicament, and lifetime value of the patients were significantly higher than those before the intervention (all P < 0.05). Decision certainty results showed that the differences between the T0, T1, and T2 time points and the interaction between groups and time were statistically significant, and the interaction was more significant at T2 (P < 0.05). CONCLUSION: VIP future care can change patients' wishes for end-of-life care, improve patients' and quality of life, and increase patient decision-making certainty.
format Online
Article
Text
id pubmed-9453040
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-94530402022-09-09 Application of VIP Care in Patients with Advanced Tumors in the Western Region of China Zheng, Xiaoqin Peng, Yanqiong Liu, Chonghua Li, Fei Zhang, Haiying Liao, Jia Wu, Guirong Zeng, Xiaomei Xie, Nan Biomed Res Int Research Article OBJECTIVE: The objective of this study is to explore the application of a very important person (VIP) intervention mode in patients with advanced tumors in the western region of China. METHODS: One hundred and sixty-three patients were randomly divided into a control and experimental groups. The control group received routine care, and the experimental group received VIP future care. The willingness to end-of-life treatment, decision-making certainty, and quality of life were compared between the two groups before intervention (T0), after intervention (T1), and 1 month after intervention (T2). RESULTS: There were no significant differences in the basic data of the two groups. Unlike the control group, the experimental group preferred palliative care at the end of T1 (P < 0.05), and the acceptance rate of cardiopulmonary resuscitation and mechanical treatment decreased significantly. After the VIP intervention, the patient was transferred to the intensive care unit (ICU) (P < 0.05). After 1 month of intervention (T2), the results showed that the overall quality of life, physical discomfort, negative emotions, care and support, survival predicament, and lifetime value of the patients were significantly higher than those before the intervention (all P < 0.05). Decision certainty results showed that the differences between the T0, T1, and T2 time points and the interaction between groups and time were statistically significant, and the interaction was more significant at T2 (P < 0.05). CONCLUSION: VIP future care can change patients' wishes for end-of-life care, improve patients' and quality of life, and increase patient decision-making certainty. Hindawi 2022-08-31 /pmc/articles/PMC9453040/ /pubmed/36093398 http://dx.doi.org/10.1155/2022/7834620 Text en Copyright © 2022 Xiaoqin Zheng et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Zheng, Xiaoqin
Peng, Yanqiong
Liu, Chonghua
Li, Fei
Zhang, Haiying
Liao, Jia
Wu, Guirong
Zeng, Xiaomei
Xie, Nan
Application of VIP Care in Patients with Advanced Tumors in the Western Region of China
title Application of VIP Care in Patients with Advanced Tumors in the Western Region of China
title_full Application of VIP Care in Patients with Advanced Tumors in the Western Region of China
title_fullStr Application of VIP Care in Patients with Advanced Tumors in the Western Region of China
title_full_unstemmed Application of VIP Care in Patients with Advanced Tumors in the Western Region of China
title_short Application of VIP Care in Patients with Advanced Tumors in the Western Region of China
title_sort application of vip care in patients with advanced tumors in the western region of china
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9453040/
https://www.ncbi.nlm.nih.gov/pubmed/36093398
http://dx.doi.org/10.1155/2022/7834620
work_keys_str_mv AT zhengxiaoqin applicationofvipcareinpatientswithadvancedtumorsinthewesternregionofchina
AT pengyanqiong applicationofvipcareinpatientswithadvancedtumorsinthewesternregionofchina
AT liuchonghua applicationofvipcareinpatientswithadvancedtumorsinthewesternregionofchina
AT lifei applicationofvipcareinpatientswithadvancedtumorsinthewesternregionofchina
AT zhanghaiying applicationofvipcareinpatientswithadvancedtumorsinthewesternregionofchina
AT liaojia applicationofvipcareinpatientswithadvancedtumorsinthewesternregionofchina
AT wuguirong applicationofvipcareinpatientswithadvancedtumorsinthewesternregionofchina
AT zengxiaomei applicationofvipcareinpatientswithadvancedtumorsinthewesternregionofchina
AT xienan applicationofvipcareinpatientswithadvancedtumorsinthewesternregionofchina